Children's Mercy Kansas City

SHARE @ Children's Mercy
Manuscripts, Articles, Book Chapters and Other Papers
3-2021

Effect of Crohn's Disease on Villous Length and CYP3A4
Expression in the Pediatric Small Intestine.
Carrie A. Vyhlidal
Children's Mercy Hospital

Brian D. Chapron
Children's Mercy Hospital

Atif Ahmed
Children's Mercy Hospital

Vivekanand Singh
Rebecca Casini

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers
Part of the Gastroenterology Commons, Pathology Commons, Pediatrics Commons, and the
Pharmacology, Toxicology and Environmental Health Commons

Recommended Citation
Vyhlidal CA, Chapron BD, Ahmed A, Singh V, Casini R, Shakhnovich V. Effect of Crohn's Disease on Villous
Length and CYP3A4 Expression in the Pediatric Small Intestine. Clin Transl Sci. 2021;14(2):729-736.
doi:10.1111/cts.12938

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for
inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact library@cmh.edu.

Creator(s)
Carrie A. Vyhlidal, Brian D. Chapron, Atif Ahmed, Vivekanand Singh, Rebecca Casini, and Valentina
Shakhnovich

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/3162

Citation: Clin Transl Sci (2021) 14, 729–736;

doi:10.1111/cts.12938

ARTICLE

Effect of Crohn’s Disease on Villous Length and CYP3A4
Expression in the Pediatric Small Intestine
Carrie A Vyhlidal1,2,*, Brian D. Chapron1, Atif Ahmed2,3, Vivekanand Singh4, Rebecca Casini5 and Valentina Shakhnovich1,2,6

Changes in absorptive capacity and first-pass metabolism in the small intestine affect oral drug bioavailability. Characterization
of such changes as a consequence of inflammation is important for developing physiologically-based pharmacokinetic (PBPK)
models for inflammatory bowel disease. We sought to elucidate the impact of small intestinal Crohn’s disease (CD) on villous length and CYP3A4 expression in children. Freshly frozen duodenal and terminal ileum (TI) biopsies from 107 children
(1–19 years) with and without CD were evaluated for active inflammation. Villous length and CYP3A4 mRNA/protein expression
were compared among regions of active and inactive inflammation in CD and controls. A twofold reduction in villous length was
observed in inflamed duodena and ilia of children with CD, but in the absence of regional inflammation, villi in CD were comparable in length to controls. Expression of CYP3A4 mRNA correlated significantly with villous length in the TI (P = 0.0003), with a
trend observed in the duodenum that did not reach statistical significance. In the presence of active inflammation, a significant
decrease in CYP3A protein expression was confirmed in the duodenum, where protein expression also correlated significantly
with villous length across diagnoses (P < 0.0001). Our findings suggest that previous observations of decreased CYP3A4 expression and function in inflamed intestine may not be due solely to downregulation by inflammatory cytokines, but also to villous
blunting and subsequent loss of surface area for protein expression. This information is relevant for PBPK model development
and could aid with dose adjustment decisions for oral CYP3A4 substrates administered during CD flare (e.g., budesonide).

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
✔ Small intestinal inflammation associated with Crohn’s
disease (CD) has the potential to alter the absorption and
first-pass metabolism of orally administered drugs metabolized by CYP3A4, the major P450 isoform in the small
intestine. However, there is currently little information
available in pediatric populations, where such information
is critical for the development of physiologically-based
pharmacokinetic (PBPK) models that could aid with appropriate drug dose selection of oral CYP3A4 substrates
during disease flare vs. remission.

Crohn’s disease (CD) is a chronic autoimmune condition
characterized by recurrent and remitting episodes of inflammation in the gastrointestinal tract. Active upper tract CD
is associated with inflammation in the small intestine that
results in histopathological changes to the intestinal absorptive epithelium, including villous blunting in the affected
intestinal regions.1,2 Because healthy villi play a critical role
1

WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This study investigates the relationships of inflammation,
villous length, and the expression of CYP3A4 and related
genes in the small intestine of children with and without CD.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ Active regional inflammation in CD was associated with
both villous length blunting and decreased mRNA/protein
expression of CYP3A4 in the small intestine.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
✔ CYP3A4 expression and villous length data presented in
this study can contribute to future PBPK model development.

in making the small intestine the major site of absorption
for most orally administered drugs, the structural changes
frequently observed in active CD have the potential to alter
oral drug bioavailability. In light of the fact that treatment of
CD frequently necessitates patients take multiple oral medications on a lifelong basis,3 it is important to characterize
the factors governing small intestinal drug disposition in CD.
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Cytochrome P450 3A4 (CYP3A4)-mediated metabolism is
the primary route of clearance for over a quarter of the most
commonly prescribed drugs.4 In addition to high hepatic expression, CYP3A4 is the most abundant cytochrome P450
isoform in the small intestine and is capable of extensively
metabolizing many orally absorbed drugs during first-pass
metabolism.5,6 Much is known about the regulation of CYP3A4
expression in the healthy adult intestine, including its transcriptional regulation by specific nuclear receptors such as
PXR and FXR.7–9 However, there is currently a paucity of published literature regarding alterations in CYP3A4 expression in
CD, with a critical information gap for pediatric patients.
Notable among the existing published data are results
from an in vivo pharmacokinetic study in adults with CD that
attempted to estimate the fraction of a CYP3A4 substrate,
midazolam, metabolized in the intestine during first-pass.10
The authors of the study estimated an average fivefold lower
intestinal extraction ratio of midazolam in adults with CD than
previously reported for healthy subjects.10 One major limitation
of the study design was that the independent contributions of
the fraction absorbed (Fa) and the fraction escaping intestinal first-pass metabolism (Fg) could not be differentiated. This
separation of Fa and Fg is critical because some histological
pathologies that occur in CD (e.g., villous blunting and reductions in tight junction integrity) may independently alter drug
access to the portal venous supply,2,11 thereby altering the Fa
and potentially confounding the estimation of changes in Fg
and CYP3A4-mediated intestinal first-pass metabolism.
Direct assessment of CYP3A4 expression in small intestinal biopsies provides a way to circumvent the issue of
conflating changes in the diffusion and partitioning of drugs
across the epithelial barrier with changes in the intrinsic catalytic activity of CYP3A4 in the small intestinal enterocytes.
Using archived formalin fixed, paraffin embedded duodenal and ileal biopsies from children with CD, we previously
demonstrated decreased mRNA expression of CYP3A4 and
NR1I2 (the gene encoding for PXR) in inflamed vs. noninflamed small intestine from the same individuals.12 These
observations mirrored similar findings of reduced intestinal
CYP3A4 mRNA expression in celiac disease,13 another inflammatory disorder that, similarly to CD, results in intestinal
villous blunting.2 Collectively, these findings raise the question of whether villous blunting and the subsequent reduction
in intestinal surface area, or inflammation/disease per se,
modulate intestinal CYP3A4 expression, and, if so, to what
extent. Such mechanistic insights are relevant for the development of physiologically-based pharmacokinetic (PBPK)
models of drug disposition in the intestine, particularly for
conditions characterized by recurrent and remittent bouts of
intestinal pathology where drug dose adjustments may be
warranted based on variability in local intestinal drug metabolism during active vs. inactive phases of disease. Thus, our
primary objective in this study was to investigate the relationships of inflammation, villous length, and CYP3A4 expression
in the small intestine of children with and without CD.
Given the putatively “synergistic” nature of the concerted actions of CYP3A4 and the active apical efflux
transporter P-gp in the small intestine,14 genes encoding
for P-gp (ABCB1), PXR (NR1I2) and FXR (NR1H4), two
nuclear receptors known to regulate CYP3A4 and ABCB1
Clinical and Translational Science

gene expression, were also evaluated.15,16 Additionally, the
expression of the gene encoding for IL8 (CXCL8), an inflammatory chemokine that is elevated in CD, was also assessed
as an added means of quantifying intestinal inflammation.17
VIL1 expression was determined as a marker of enterocyte
content of the biopsies as well.
METHODS
Collection of samples
In addition to standard-of-medical-care clinical and histopathology review, fresh flash-frozen duodenal and terminal ileum
(TI) mucosal biopsies from 39 children with CD (1–19 years
of age) who were treatment-naïve (i.e., no steroids, immunomodulators, or biologics), and 68 age and sex-matched
children without inflammatory bowel disease (IBD) were
assessed for villous length and mRNA expression. Standardof-care endoscopy with biopsy was routinely performed after
at least 8 hours of fasting. Biopsies from children without CD
(i.e., controls) were collected from children undergoing standard-of-medical-care upper and lower endoscopies to rule
out organic causes of common gastrointestinal (GI) complaints (e.g., abdominal pain). All routinely biopsied sites (i.e.,
esophagus, stomach, and small and large intestine) were
reviewed by two independent pathologists to confirm that inflammation and/or any other organic pathology was absent.
Ultimately, these children were diagnosed with functional or
psychosomatic complaints, but healthy GI tracts with no evidence of GI pathology. Children without IBD were overenrolled
in order to assess variability in intestinal villous length across
the pediatric age spectrum. For all samples, the extent of inflammation was assessed by two independent, experienced
pediatric pathologists. The villous length was measured
using Infinity Analyze Software (Teledyne Lumenera, Ottawa,
Canada) with built-in morphometric capabilities. A line was
drawn from the villous tip to the base where it curves to blend
with the crypt and its length was measured in micrometers.
This study was approved by the Children’s Mercy Pediatric
Institutional Review Board. Descriptive statistics for the study
population are provided in Table 1.
Gene expression
Using the Allprep DNA/RNA/miRNA extraction kit (Qiagen,
Valencia, CA) according to manufacturer’s recommendations, RNA was extracted from intestinal mucosal biopsy
samples obtained during standard-of-care endoscopy.
RNA quantity was determined with a NanoDrop ND-1000
spectrophotometer (ThermoFisher Scientific, Waltham,
MA) and quality with an Experion automated electrophoresis system (BioRad, Hercules, CA). Total RNA (200 ng) was
reverse transcribed using the High-Capacity RNA-to-cDNA
Kit (Applied Biosystems, Foster City, CA). Eight duodena
and eight TI samples (3 from children with CD, and 5 without CD) were excluded from gene expression analyses due
to lack of sufficient material for RNA extraction. An additional four duodenal (4 from children with CD) and three TI (1
from a child with CD, and 2 without CD) RNA samples were
excluded from gene expression analyses due to GAPDH
mRNA values below the limits of quantification for the assay.
For all other samples, expression of NR1I2 (Hs00243666_
m1), NR1H4 (Hs01026590_m1), CXCL8 (Hs99999034_m1),
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Table 1 Descriptive statistics of the study population
CD subgroups
Control-all

Control-no meds

CD-all

CD-Duo

CD-TI

CD-both

CD-remission

Number of participants

68 duo
61 TI

21 duo
21 TI

39 duo
37 TI

5 duo
5 TI

15 duo
14 TI

11 duo
11 TI

8 duo
7 TI

Age, years [range]

13.4 ± 3.8
[2.0–18.1]

12.7 ± 4.2 [2.0–18.1]

12.7 ± 3.5
[1.3–19.3]

13.6 ± 2.6
[7.5–17]

13.0 ± 2.3
[8.6–16.6]

9.5 ± 4.7 [1.3–13.6]

14.7 ± 3.7
[10.2–19.3]

Female (%)

35 (51)

9 (43)

13 (33)

1 (20)

4 (27)

4 (36)

4 (50)

Duodenum villous
length, μmb

471 ± 72

441 ± 70

396 ± 150a

279 ± 138a

483 ± 81

262 ± 130a

492 ± 98

TI villous length, μmb

509 ± 74

500 ± 64

268 ± 184a

471 ± 50

205 ± 150a

179 ± 166a

389 ± 176a

CD, Crohn’s disease; Duo, duodenum, TI, terminal ilium.
a
Indicates statistically significant difference in villous length from “Control-all” group for the corresponding tissue.
b
Villous length is reported as average ± SD.

CYP3A4 (Hs00604506_m1), VIL1 (Hs_00200229_m1),
ABCB1 (Hs00184500_m1), and GAPDH (4333764) was
determined via real-time polymerase chain reaction using
PerfeCTa FastMix (Quanta Biosciences, Beverly, MA). Each
gene expression assay was performed in triplicate for each
sample and results were normalized to the expression of
GAPDH. In this study, we considered the expression of
VIL1 as an independent marker of villous length, therefore,
GAPDH was used to normalize gene expression rather than
VIL1, commonly used in other gene expression studies in
the small intestine. Similar differences in gene expression
were observed between groups when VIL1 was used to
normalize gene expression in this dataset.
Immunohistochemistry
On the basis of tissue availability, a subset of duodenal
biopsy samples including 35 non-IBD controls and 34 patients with CD (15 with active duodenal inflammation and
19 CD without duodenal inflammation) were subjected to
immunohistochemistry (IHC) staining for CYP3A4 protein expression. Briefly, a polyclonal antibody for CYP3A4
(ThermoFisher Scientific, Rockford, IL) was used at a dilution of 1:1000. After antigen retrieval, automated IHC
was performed in a Leica BOND-MAX instrument (Leica
Biosystems, Wetzlar, Germany), using standard protocols
that included primary antibody, a secondary antibody, a
polymer conjugate, and a coloring reagent. Staining in the
top of mucosal villi was evaluated in the study samples and
compared with staining pattern in normal pediatric mucosa,
which served as an internal positive control. Postnatal liver
tissue, known to abundantly express CYP3A4, served as an
external positive control. The intensity of the staining was
defined a priori according to the following scoring system:
(0) negative or complete absence of any staining; (1) weak
staining or marked loss of normal staining; (2) patchy interrupted staining or decreased intensity of normal staining;
or (3) normal staining, with staining intensity similar to normal mucosa. During sample analysis, scores 0 and 1 were
binned together, as consensus could not be reached between the rating pathologists for several samples with low/
no staining for CYP3A4. Because the TI is generally less
relevant than the duodenum in oral drug absorption, IHC
staining was not performed on TI biopsies.

Statistical analysis
Villous length and log-transformed normalized gene expression levels were compared in controls without IBD
and children with CD (with and without active regional inflammation in the intestine on histopathology). Statistical
analyses were performed using JMP 14.2.0 (SAS Institute,
Cary, NC). One-way analysis of variance (ANOVA) was conducted on expression data for all six genes of interest or
villous length measurements within a given intestinal region (duodena and TI) across the three conditions: non-IBD
controls, CD with inflammation in the region of interest (duodena or TI), and CD without inflammation in the region of
interest. Comparison of villous length was also stratified
by IHC staining grade. A Pearson χ2 test of independence
was performed to examine the relationship between staining grade of CYP3A4 and CD disease/inflammation state.
Post hoc pairwise comparisons were conducted on all data
with significant results using Tukey’s Honest Significant
Difference.
RESULTS
Villous length
There was no observable trend between age and villous
length in the duodenum or TI across the study population (n = 107 duodenum and n = 98 TI, age 1–19 years),
regardless of disease or inflammation status (Figure 1).
Concomitant medication use at the time of endoscopy
(e.g., acid suppression drugs and antihistamines) did not
appear to influence villous length (control-no meds vs.
control-all; Table 1). A statistically significant, approximately twofold reduction in villous length was observed
in both the duodenum and TI in the presence of active
inflammation associated with CD, compared with CD without active regional inflammation on histopathology, or in
controls without IBD (P < 0.0001; Figure 2). Villous length
in the duodenum did not differ significantly between
controls and children with CD without active regional
inflammation (486 ± 85 µm vs. 471 ± 72 µm duodenum;
P = 0.7). In contrast, villous length in the terminal ileum
was statistically significantly lower in children with CD
without active regional inflammation relative to controls
(509 ± 74 µm controls vs. 423 ± 140 µm CD without active
inflammation; P = 0.04).
www.cts-journal.com
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Figure 2 Effect of Crohn’s disease (CD)-associated regional
inflammation on villous length. Both mean duodenal
(289 ± 140 µm) and ileal (194 ± 154 µm) villous length was
significantly reduced in children with active CD and regional
inflammation, compared with children with CD without active
regional inflammation (503 ± 69 µm duodenum and 423 ± 140 µm
ileum) or controls (495 ± 67 µm duodenum and 509 ± 74 µm
ileum; P < 0.0001).

600

400

200

0
0

600

5

10

Age (years)

15

20

No CD: Controls
CD: Regional inflammation
CD: No Regional inflammation

Figure 1 Ontogeny of small intestinal villous length in the
presence and absence of Crohn’s disease (CD)-associated
inflammation. There was no apparent association between age
and villous length across the age range studied (1–19 years) in
either the duodenum or terminal ileum regardless of disease or
inflammation status.

Gene expression
Disease-specific differences
Statistically significant differences in CYP3A4 mRNA expression were noted in the TI determined by one-way
ANOVA (F(2,93) = 3.89, P = 0.024; Figure 3). Specifically,
CYP3A4 gene expression was reduced in ileal tissue of
children with CD and active ileal inflammation compared
with children without CD (P = 0.021). CYP3A4 expression in
the TI was not significantly different between children with
CD without active inflammation and controls (P = 0.98).
Decreased CYP3A4 gene expression in inflamed duodenal
tissue of children with CD was also noted, but did not reach
statistical significance (one-way ANOVA F(2,92) = 1.88,
P = 0.16). No significant differences or trends in expression
of other CYP3A4-related genes or VIL1 were noted across
study groups.
Statistically significant differences in expression were also
observed in both the duodenum and TI for CXCL8, which
encodes IL-8, a marker of inflammation (one-way ANOVA
F(2,92) = 4.25, P = 0.02, duodenum; and F(2,93) = 20.61,
P < 0.0001, TI). In the duodenum, CXCL8 expression was
higher in children with CD with active inflammation relative to controls (Figure 3, P = 0.02). In the terminal ileum,
CXCL8 expression was significantly higher in children with
Clinical and Translational Science

CD, both with and without active TI inflammation on histopathology, compared with controls (P < 0.0001 and P = 0.007,
respectively).
Adding gender as a covariate did not affect the above
results.
Regional differences
In controls without IBD, gene expression of CYP3A4,VIL1,
andNR1I2 was significantly greater in the duodenum than
the TI (P < 0.0001). This gradient in NR1I2 gene expression was lost in samples from patients with CD (corrected
P > 0.05), whereas it was maintained for CYP3A4 and VIL1.
Conversely, expression of ABCB1 and NR1H4 was significantly greater in the TI than the duodenum in both controls
(P < 0.0001) and children with CD (P = 0.02 and P = 0.006,
respectively). Expression of CXCL8 was also significantly
greater in the TI than the duodenum, but only in children
with CD (both with and without active inflammation on histopathology (Figure 3).
mRNA correlations with villous length
Overall, mRNA expression did not correlate with villous
length, except for CYP3A4 in the TI across the entire
study population, independent of disease status (r = 0.38,
P = 0.0003). Expression of CXCL8 mRNA was inversely correlated with villous length (r = −0.55, P < 0.0001), as well as
expression of CYP3A4 in the TI (r = −0.42, P < 0.0001).
Immunohistochemistry of CYP3A4
Similar to observations in adults,18 expression of CYP3A4 protein in pediatric controls was restricted mostly to the villous
tips and was enriched along the apical border of the duodenal
enterocytes. The pattern for CYP3A4 IHC staining was weaker,
more diffuse, and patchier in the inflamed duodenum of children with CD than in the uninflamed duodenum of children
with CD or in controls. Approximately 47%, 33%, and 20%
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Figure 3 Small intestinal mRNA expression levels for CYP3A4 and related genes in the presence and absence of Crohn’s disease
(CD)-associated inflammation. Gene expression of CYP3A4 was significantly reduced in the terminal ileum (TI) of children with CD
when active regional (i.e., ileal) inflammation was present. A similar trend was observed in the duodenum; however, it did not reach
statistical significance. Expression of CXCL8 was increased in CD in the TI in CD in the presence and absence of active regional (i.e.,
TI) inflammation. The expression of CYP3A4, ABCB1, NR1I2, and VIL1 was significantly different between duodenum and TI only in
controls without CD, and expression of CXCL8 differed significantly between the duodenum and TI only in CD with active inflammation
in one region but not the other.

of patients with CD and active duodenal inflammation scored
0/1, 2, and 3, respectively, on IHC staining, compared with
5%, 11%, and 84% of patients with CD but without duodenal
inflammation and 3%, 17%, and 80% of controls without IBD
(Figure 4). A χ2 test of independence found a statistically significant relationship between CD disease/inflammation status
and CYP3A4 staining grade (Pearson χ2 = 25.6, P < 0.0001).
Higher staining grades were significantly associated with
longer mean villous length (one-way ANOVA F(2,66) = 69.3,
P < 0.0001). Post hoc analysis confirmed differences among
all three possible pairings of IHC staining grades (P < 0.0001).
When stratified by disease and inflammation state, visual inspection of the relationship between CYP3A4 IHC staining
grade and villous length generally suggests that, although
relatively lower duodenal CYP3A4 protein expression is more

common in CD with active duodenal inflammation, villous
length appears similar within a given staining grade irrespective of underlying disease or inflammation status (Figure 5).
DISCUSSION
CD is an inflammatory illness that often manifests in histopathological changes along the GI tract.1,2 Small intestinal
involvement in CD has the potential to alter the absorption
and first-pass metabolism of orally administered drugs.
However, there is currently little published information on
the intestinal disposition of drugs in children with CD. In this
study, we sought to elucidate the effects of CD, both during
active small intestinal inflammation and remission, on the
relationship between enterocytic CYP3A4 expression and
www.cts-journal.com
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Figure 4 Prevalence of duodenal CYP3A4 protein expression patterns in presence and absence of Crohn’s disease (CD)-associated
duodenal inflammation. Representative images of staining grades are displayed in the upper panels. Prevalence of staining grades by
disease and duodenal inflammation status are displayed below. Grade 3 staining (i.e., normal apical pattern) was comparable between
controls without CD and children with CD but without active duodenal inflammation. Lower staining grades (0/1 and 2) were more
prevalent in biopsies from children with CD and active duodenal inflammation.

Duodenal Villous length ( m)

villous length. Using duodenal and TI tissue collected from
individuals with CD and healthy controls during routine
biopsy, we evaluated villous length, CYP3A4 mRNA expression, and protein expression. Because the mass of tissue
collected during routine biopsies in children is especially
small, currently available targeted proteomic approaches
are insufficiently sensitive to measure CYP3A4 content
in a quantitative manner. As such, we opted to evaluate
CYP3A4 protein expression qualitatively via IHC staining.
Although the interpretation of the IHC-derived enzyme expression data has some limitations, it does demonstrate
that there are important differences in CYP3A4 expression
occurring during CD-associated regional inflammation.
Specifically, we observed that active regional inflammation in CD was associated with both villous length blunting
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CD: Regional inflammation
CD: No Regional inflammation
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Figure 5 Association between villous length and CYP3A4 protein
expression. CYP3A4 immunohistochemistry (IHC) staining
category (ordinal variable) correlated with villous length in the
duodenum where higher protein staining was noted in samples
with longer villi, independent of disease or inflammation. CD,
Crohn’s disease.
Clinical and Translational Science

and decreased mRNA/protein expression of CYP3A4 in the
small intestine. Although the trend toward decreased CYP3A4
mRNA expression in the inflamed duodenum of children with
CD did not reach statistical significance, as it did in the TI,
significant reduction in CYP3A4 protein expression was
confirmed by IHC staining in the presence of duodenal inflammation (Figure 4). IHC staining grade also correlated
with villous length across all samples (Figure 5). Observation
of lower IHC staining in the duodena of controls with shorter
villi, in the absence of increased tissue CXCL8 expression or
inflammation on histopathology, suggests that villous length
may exert an independent effect on CYP3A4 expression in
the gut. This could suggest that previous observations of reduced intestinal CYP3A4 activity in CD10 may not be solely the
result of the direct action of CD-associated inflammatory cytokines on CYP3A4 transcriptional regulation. Rather, reduced
CYP3A4 expression may also be secondary to loss of enterocyte surface area along the shorter duodenal villi caused by
intestinal inflammation. However, we acknowledge that the
relationship between villous length and protein expression is
complex and mechanistic studies are beyond the scope of this
report.
If altered, CYP3A4 expression is associated with villous blunting and/or active disease in the duodenum,
as our data suggest, dose adjustments for oral CYP3A4
substrates may be necessary during times of CD flare vs.
remission. This is particularly relevant for oral CYP3A4
substrates budesonide and midazolam, as budesonide is
commonly prescribed for IBD flare, in an attempt to limit
systemic corticosteroid exposure, and midazolam is used
as an anxiolytic before endoscopy. Although changes in
ileal CYP3A4 expression may also contribute to the disposition of these drugs, CYP3A4 expression decreases from
proximal to distal small intestine,19–21 as supported by our
mRNA data. Thus, the relative contribution of CYP3A4
changes in the TI is expected to be lower than changes
in the duodenum. For this reason, IHC staining in the TI
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was not performed, especially as additional tissue was not
always available for staining.
Our data also provide a basis for further investigations
into the utility of orally administered CYP3A4 drug probes
and their metabolism as noninvasive surrogate markers of
intestinal epithelial health and inflammation. This biomarker
approach has been previously evaluated with some promise
in celiac disease22 but not yet in CD, where it could offer
a convenient alternative to endoscopy, particularly as the
focus of therapeutic end points shifts from symptom relief to
mucosal healing for CD.23
In addition to CYP3A4 expression, we also evaluated
gene expression for ABCB1 (gene encoding for P-gp), an
active efflux transporter localized in the apical brush border
of the small intestine that is capable of independently reducing the fraction of drug absorbed in the small intestinal
epithelium.24 P-gp and CYP3A4 are believed to be coregulated by a number of the same nuclear receptors in the
gut (e.g., PXR).15,25 In our study, no significant differences
were noted in ABCB1 or NR1I2 (gene encoding for PXR) in
inflamed vs. noninflamed small bowel. However, the typical proximodistal gradient for NR1I2 observed in controls,
was absent in children with CD, suggesting that this gene
is also modulated by disease, consistent with our previous
findings.12
Four children without active TI inflammation on histopathology were noted to have granulomas present. Whereas
only present in a subset of patients, granulomas are considered markers of CD and have been suggested to indicate
a more aggressive disease phenotype26; although this is
somewhat controversial. Based on the absence of active inflammation on histopathology, samples from these children
were grouped with other children with CD without active inflammation. However, both villous length and the expression
of the inflammatory cytokine, CXCL8, was highly variable
in these biopsies suggesting that the disease may not be
in complete remission for all of these children. Variability
in disease phenotype in the TI (e.g., granulomas) may also
help explain our observation of reduced villous length and
increased CXCL8 expression in the TI, but not the duodenum, of children with CD without active inflammation, when
compared with controls.
Understanding the contribution of intestinal inflammation to variability in the expression and function of drug
metabolizing enzymes and transporters in the intestine is
important for the development of PBPK models. Our characterization of age-related and disease-related changes
in intestinal villous length is equally important for the development of maturation functions for scaling effective
absorptive surface area for pediatric PBPK models. In our
study, we confirm previous observations of stability in intestinal villous length after 1 year of age,27 in the absence
of intestinal disease. We also demonstrate that villous
length is reduced twofold in the presence of small bowel
inflammation from CD, and as such could contribute
significantly to reduction in surface area for oral drug absorption. Although the observations from our study alone
are insufficient to generate a bottom-up PBPK model of
pediatric CD, we believe PBPK modeling is ideally suited
for pediatric patients with this diagnosis.

First, pediatric patients represent a minority of the patient
population,28 which makes enrollment of children in adequately powered trials challenging. Second, the pediatric
disease phenotype is distinct and generally more aggressive
than adult-onset disease29; therefore, it may be inappropriate to extrapolate adult pharmacology data to children
without accounting for both ontogeny and disease severity
in the intestine. In addition, few data exist regarding the expression of drug metabolizing enzymes and transporters in
adults with CD. For example, Wilson et al. reported lower
ileal CYP3A4 expression and reduced colonic expression of
P-gp in adults with CD.30 There are no studies that have investigated alterations of gene expression in the duodenum
of adults with CD. Last, the remitting and relapsing nature
of CD, if captured effectively in the small intestine compartment of a PBPK model, could aid with appropriate dose
adjustments of orally administered drugs during disease remission and flare. Our hope is that the CYP3A4 expression
and villous length data presented herein can inform future
PBPK model development.
In summary, our data suggest that expression of
CYP3A4, one of the most abundant CYP isoforms in the
small intestine,5,6 increases with increasing villous length,
which is significantly blunted in active CD due to regional
intestinal inflammation. Villous blunting, in addition to
modulation by inflammatory cytokines, may contribute to
previous observations of reduced CYP3A4 expression and
activity in the small intestines of children with CD. Villous
blunting may also account for decreased total absorptive capacity in the small intestine, which may influence
the relative bioavailability of orally administered drugs
during disease flare vs. remission. Future studies could
test this hypothesis through PBPK simulation, followed
by confirmation in vivo. Ideally, future translational studies
to support further PBPK model development would use
more advanced technologies, such as the rapidly evolving
field of targeted proteomics, to obtain measurements of
enzyme expression that are not currently possible due to
constraints of routine mucosal biopsy size (i.e., ~ 1 mg).
Such quantitative data would be crucial for the informed
development of disease-specific PBPK models capable of
providing tailored dosing for pediatric patients with CD,
and potentially other conditions affecting the small intestine (e.g., celiac disease).
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